Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Muscle recovery differs between sexes, new study reveals

NCT ID NCT04151901

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how middle-aged men and women lose muscle after a week of not using one leg, and how they recover with exercise. Researchers will measure muscle strength, size, and genetic activity to find sex-specific differences. The goal is to learn more so future treatments can be tailored to each sex.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Resistance exercise rehabilitation and walking-based rehabilitation
What this could lead to
If successful, this could help design better, sex-specific rehabilitation programs for middle-aged people after periods of inactivity.
What could go wrong
This is a small, early-phase study with only 37 participants, so results may not apply to everyone. It focuses on understanding mechanisms, not on testing a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

37 people

The number who actually took part.

Started

Aug 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. All races and ethnic backgrounds 2. Men and women, age 50-65 years 3. Generally healthy (see exclusion criteria) 4. Able and willing to provide informed consent 5. Ability to speak and read English 6. Post-menopausal women (no menses within the last 12 months) 7. Body mass index: 18.5-35 kg/m2 or BMI\>35 if thigh adiposity does not impair muscle biopsy Exclusion Criteria: 1. Compromised musculoskeletal function that precludes safe participation or use of crutches 2. Pre-menopausal women 3. Hypogonadal men (testosterone \<300 ng/dL) 4. Women taking hormone replacement therapy (HRT) 5. Sarcopenia (European Working Group on Sarcopenia in Older People, EWGSOP102) 6. Clinically significant heart disease (e.g. New York Heart Classification greater than grade II; ischemia) 7. Peripheral vascular disease 8. History of claudication 9. Pulmonary disease 10. History of systemic or pulmonary embolus 11. Uncontrolled blood pressure (systolic BP\>170, diastolic BP\>95 mmHg) 12. Impaired renal function (creatinine \>1.5 mg/dl) 13. Anemia (hematocrit \<33) 14. Untreated thyroid disease (abnormal TSH) 15. A recent history (\<12 months) of GI bleed 16. Diabetes mellitus or other untreated endocrine or metabolic disease 17. Electrolyte abnormalities 18. Any history of stroke, hypo- or hyper-coagulation disorders 19. Employment requiring long (\>1 h) uninterrupted period of standing 20. Inability to meet study travel requirements (e.g. manual geared car) 21. Recent history of balance issues or falls. 22. Recent (3 years) treated cancer other than basal cell carcinoma 23. Systemic steroids, anabolic steroids, growth hormone or immunosuppressant use within 12 months 24. Recent (2 months) adherence to a weight-loss or weight-gain diet 25. Weight change of 5% or more in previous 6 months 26. Body mass index \>30 or excess body fat that compromises muscle biopsy collection 27. Acute infectious disease or chronic infection 28. Alcohol or drug abuse 29. Any other condition or event considered exclusionary by study physician

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrophy of muscle due to disuse are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

muscular atrophy Muscular Disorders, Atrophic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas, 78229, United States

  • University of Texas Medical Branch

    Galveston, Texas, 77555, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.